© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Hematology
What Is the Role of Allogeneic-SCT in Adult Acute Lymphoblastic Leukemia in the Era of Targeted Therapies?
October 21, 2020
There are several indications for the use of allo-SCT in adults. With the implementation of targeted therapies, these are continuously changing.
FDA-Approved Oral Hypomethylating Agent Regimen Excites MDS Landscape
October 20, 2020
Guillermo Garcia-Manero, MD, discusses how the recently approved combination regimen of decitabine and cedazuridine fits into the treatment landscape for patients with myelodysplastic syndromes.
Safety of Guadecitabine Consistent Across Phase 3 Trials in Various Hematologic Malignancies
October 16, 2020
Two phase 3 clinical trials demonstrated consistent safety findings with the expected safety profile of guadecitabine as treatment of 2 patient populations, including patients with previously treated acute myeloid leukemia in ASTRAL-2 and patients with previously treated myelodysplastic syndrome or chronic myelomonocytic leukemia in ASTRAL-3.
Investigational Agent Achieves All Secondary End Points in Phase 3 Study of Hematologic Malignancies
October 12, 2020
Omidubicel as treatment of patients with high-risk hematologic malignancies induced rapid platelet engraftment and a reduction in the number of infections and hospitalizations, meeting all 3 secondary end points of a phase 3 clinical trial.
FDA Grants Breakthrough Therapy Designation to CD123-Directed Antibody-Drug Conjugate
October 05, 2020
The FDA granted a Breakthrough Therapy designation to IMGN632 as treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasms.
FDA Issues Complete Response Letter to Remestemcel-L for Pediatric Steroid-Refractory Acute GVHD
October 02, 2020
The FDA issued a Complete Response Letter to remestemcel-L for the treatment of pediatric patients with steroid-refractory acute-graft-versus-host disease.
Pennsylvania Society of Oncology & Hematology Welcomes Arturo Loiaza-Bonilla, MD, MSEd, as New President
September 30, 2020
Arturo Loaiza-Bonilla, MD, MSEd, FACP ascended to the presidency of the Pennsylvania Society of Oncology, albeit virtually, during the society’s Annual Scientific Conference held via ZOOM on September 25.
Encouraging ORR Observed With CLR 131 as CLOVER-1 Heads To Pivotal Stage
September 29, 2020
CLR 131, a phospholipid ether molecule, is showing promising disease control in an ongoing phase 2 study as treatment of patients with relapsed or refractory lymphoplasmacytic lymphoma and Waldenström macroglobulinemia, according to initial study results.
Ali Explores Pivotal Trial of Ruxolitinib in Acute GVHD
September 29, 2020
Haris Ali, MD, discussed the case of a 48-year-old patient with acute graft-versus-host disease.
Comparing BTK Inhibitors in Patients With B-Cell Malignancies
September 28, 2020
Ian W. Flinn, MD, PhD, discusses the Bruton’s kinase inhibitors available for patients with B-cell malignancies and how they compare.